Symbols

ACAD

Acadia Pharmaceuticals·NASDAQ

--(--)

ACAD fundamentals

ACAD Q4 2025 Earnings

Acadia Pharmaceuticals (ACAD) released its earnings on Feb 25, 2026: revenue was 283.99M (YoY +9.39%), missed estimates; EPS was 1.6 (YoY +86.05%), beat estimates.

Revenue / YoY

283.99M

+9.39%

EPS / YoY

1.6

+86.05%

Report date

Feb 25, 2026

ACAD Earnings Call Summary for Q4,2025

Revenue Milestone: FY25 adjusted revenue surpasses $1 billion for first time at $1.08 billion (14% YoY growth).
NUPLAZID Growth: Q4 net sales $189 million (17% YoY); 2026 guidance $760-790 million (10-14% growth).
DAYBUE Expansion: Q4 sales $110 million (13% YoY); 2026 STIX-driven growth to $460-490 million.
Pipeline Momentum: Remlifanserin Phase II ADP readout expected Q3 2026; ACP-271 first-in-human study begins Q1 2026.
Financial Strength: FY26 total revenue guidance $1.22-1.28 billion; $250 million one-time tax benefit.

Earnings

EPS

Revenue

Revenue & Expenses

ACAD has released its 2025 Q4 earnings report, with revenue of 283.99M, reflecting a YoY change of 9.39%, and net profit of 273.57M, showing a YoY change of 90.32%. The Sankey diagram below clearly presents ACAD's revenue sources and cost distribution.

Key Indicators

Acadia Pharmaceuticals (ACAD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Acadia Pharmaceuticals (ACAD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Acadia Pharmaceuticals (ACAD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Acadia Pharmaceuticals (ACAD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown